Anaphylactic shock depends on PI3K and eNOS-derived NO

DSpace/Manakin Repository

Anaphylactic shock depends on PI3K and eNOS-derived NO

Citable link to this page


Title: Anaphylactic shock depends on PI3K and eNOS-derived NO
Author: Cauwels, Anje; Janssen, Ben; Buys, Emmanuel; Sips, Patrick; Brouckaert, Peter

Note: Order does not necessarily reflect citation order of authors.

Citation: Cauwels, A., Ben Janssen, Emmanuel Buys, Patrick Sips, and Peter Brouckaert. 2006. “Anaphylactic Shock Depends on PI3K and eNOS-Derived NO.” Journal of Clinical Investigation 116 (8) (August 1): 2244–2251. doi:10.1172/jci25426.
Full Text & Related Files:
Abstract: Anaphylactic shock is a sudden, life-threatening allergic reaction associated with severe hypotension. Platelet-activating factor (PAF) is implicated in the cardiovascular dysfunctions occurring in various shock syndromes, including anaphylaxis. Excessive production of the vasodilator NO causes inflammatory hypotension and shock, and it is generally accepted that transcriptionally regulated inducible iNOS is responsible for this. Nevertheless, the contribution of NO to PAF-induced shock or anaphylactic shock is still ambiguous. We studied PAF and anaphylactic shock in conscious mice. Surprisingly, hyperacute PAF shock depended entirely on NO, produced not by inducible iNOS, but by constitutive eNOS, rapidly activated via the PI3K pathway. Soluble guanylate cyclase (sGC) is generally regarded as the principal vasorelaxing mediator of NO. Nevertheless, although methylene blue partially prevented PAF shock, neither 1H-[1,2,4]oxadiazole[4,3-a]quinoxalin-1-one (ODQ) nor sGCα1 deficiency did. Also, in 2 different models of active systemic anaphylaxis, inhibition of NOS, PI3K, or Akt or eNOS deficiency provided complete protection. In contrast to the unsubstantiated paradigm that only excessive iNOS-derived NO underlies cardiovascular collapse in shock, our data strongly support the unexpected concept that eNOS-derived NO is the principal vasodilator in anaphylactic shock and define eNOS and/or PI3K or Akt as new potential targets for treating anaphylaxis.
Published Version: doi:10.1172/JCI25426
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search